Cellular transdifferentiation, a phenotypic shift from adenocarcinoma to squamous cell carcinoma or neuroendocrine carcinoma, occurs in 3%–14% of EGFR‐mutant NSCLC patients, and approximately 17% of prostate cancer failed with abiraterone/enzalutamide therapy.370. This evidence concerns the gene EGFR and non-small cell lung carcinoma.